美國衛生部將與Regeneron合作開發冠狀病毒疫苗
https://reut.rs/2Osvoap
goole翻.
（美國路透社）-美國衛生與公共服務部周二表示，它正在與Regeneron
Pharmaceuticals Inc合作開發冠狀病毒的治療方法，這使該藥物製造商成為參與開發這
種療法的最新成員。
此舉是在2017年與該公司達成的先前協議的基礎上擴大的，該協議旨在開發對公眾構成重
大風險的病原體的治療方法。2017年，再生元與HHS部門合作開發了埃博拉病毒治療方法
。
該機構說，這家製藥商將使用與開髮用於治療剛果民主共和國的埃博拉病毒的實驗藥物相
同的技術。
Regeneron表示，它將專注於開發抗感染蛋白，即單克隆抗體。
Moderna公司，吉利德科學公司，強生公司還宣布了計劃開始對該疾病的治療工作，該疾
病已經影響了中國20,000多人。
--
原文
(Reuters) - The U.S. Department of Health and Human Services said on Tuesday
it was partnering with Regeneron Pharmaceuticals Inc to develop a treatment
for the coronavirus, making the drugmaker the latest to join the race to
develop a therapy.
The move expands on a previous agreement with the company in 2017 to develop
treatments for pathogens that pose significant risk to the public. Regeneron
had partnered with an HHS unit to develop treatments for Ebola in 2017.
The drugmaker will use the same technology that was used to develop an
experimental drug to treat Ebola in the Democratic Republic of Congo, the
agency said.
Regeneron said it would focus on developing infection-fighting proteins known
as monoclonal antibodies.
Moderna Inc, Gilead Sciences Inc, Johnson & Johnson have also announced plans
to begin work on a treatment for the outbreak, which has affected over 20,000
people in China.
--
現在上車追一波？萊布萊得急阿ＸＤ
美股開盤已經在爬生惹．．．
--
https://reut.rs/2Osvoap
goole翻.
（美國路透社）-美國衛生與公共服務部周二表示，它正在與Regeneron
Pharmaceuticals Inc合作開發冠狀病毒的治療方法，這使該藥物製造商成為參與開發這
種療法的最新成員。
此舉是在2017年與該公司達成的先前協議的基礎上擴大的，該協議旨在開發對公眾構成重
大風險的病原體的治療方法。2017年，再生元與HHS部門合作開發了埃博拉病毒治療方法
。
該機構說，這家製藥商將使用與開髮用於治療剛果民主共和國的埃博拉病毒的實驗藥物相
同的技術。
Regeneron表示，它將專注於開發抗感染蛋白，即單克隆抗體。
Moderna公司，吉利德科學公司，強生公司還宣布了計劃開始對該疾病的治療工作，該疾
病已經影響了中國20,000多人。
--
原文
(Reuters) - The U.S. Department of Health and Human Services said on Tuesday
it was partnering with Regeneron Pharmaceuticals Inc to develop a treatment
for the coronavirus, making the drugmaker the latest to join the race to
develop a therapy.
The move expands on a previous agreement with the company in 2017 to develop
treatments for pathogens that pose significant risk to the public. Regeneron
had partnered with an HHS unit to develop treatments for Ebola in 2017.
The drugmaker will use the same technology that was used to develop an
experimental drug to treat Ebola in the Democratic Republic of Congo, the
agency said.
Regeneron said it would focus on developing infection-fighting proteins known
as monoclonal antibodies.
Moderna Inc, Gilead Sciences Inc, Johnson & Johnson have also announced plans
to begin work on a treatment for the outbreak, which has affected over 20,000
people in China.
--
現在上車追一波？萊布萊得急阿ＸＤ
美股開盤已經在爬生惹．．．
--
All Comments